Development of Polymeric Carriers Having M Cell Homing Peptide for Targeted Oral Vaccine Delivery by 장도
 
 
저 시-비 리-동 조건 경허락 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
l 차적 저 물  성할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적  허락조건
 확하게 나타내어야 합니다.  
l 저 터  허가를  러한 조건들  적 지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 적  할 수 없습니다. 
동 조건 경허락. 하가  저 물  개 , 형 또는 가공했  경
에는,  저 물과 동 한 허락조건하에서만 포할 수 습니다. 
A Dissertation 
 for the Degree of Doctor of Philosophy 
 
 Development of Polymeric Carriers Having M Cell 
Homing Peptide for Targeted Oral Vaccine Delivery 
 
표적형 경구 백신 전달을 위한 M 세포 표적형 펩타이드 작용기 











Department of Agricultural Biotechnology 
Graduate School 
Seoul National University 
 
농 학 박 사 학 위 논 문 
 
Development of Polymeric Carriers Having M Cell 
Homing Peptide for Targeted Oral Vaccine Delivery 
 
표적형 경구 백신 전달을 위한 M 세포 표적형 펩타이드 작용기 도입 
고분자 전달체의 개발 
 
지도교수 최윤재 
이 논문을 농학박사학위논문으로 제출함 
2014 년 11 월 
서울대학교 대학원 농생명공학부 
장 도 
장도의 박사학위논문을 인준함 
2014 년 12 월 
 
위 원 장                                     (인) 
부 위 원 장                                  (인) 
위 원                                        (인) 
위 원                                        (인) 






Compared to other administrative route, oral delivery of vaccine has 
been received considerable attraction due to providing patient compliances, 
easy handling, low cost of production, eliminating the injection pain and 
infection risks, and exerting both systemic and local immune responses. 
However, low oral bioavailability, degradation in acidic stomach and by 
gastric enzymes limit the applications of orally delivered drugs including 
vaccine and probiotics. Polymeric delivery carriers offer potential benefits 
to limit afore-mentioned problems by protecting the incorporated bioactive 
agents from the harsh gastric environments.  
In the first approach, M cells, the key players of the mucosal immunity 
induction, are one of the intestinal factors for the efficient delivery of 
vaccines to mucosal immune tissues. To get M cell targeting, we have 
developed an efficient oral vaccine carrier that constitutes poly 
(lactic-co-glycolic acid) (PLGA) microparticle coated with M cell targeting 
peptide. In this study, a membrane protein B of Brachyspira hyodysenteriae 
(BmpB) as a model vaccine against swine dysentery was loaded into porous 
PLGA microparticles (MPs). The PLGA MPs was further coated with the 
water-soluble chitosan (WSC) conjugated with M cell homing peptide 
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(CKS9) to prepare BmpB-CKS9-WSC-PLGA MPs. Oral immunization of 
BmpB vaccine with CKS9-WSC-PLGA MPs in mice showed elevated 
secretory IgA (sIgA) responses in the mucosal tissues and systemic IgG 
antibody responses, providing an efficient immune response. Specifically, 
the immunization with these MPs demonstrated to induce both Th1- and 
Th2-type responses based on elevated IgG1 and IgG2a titers. The elevated 
immune responses were attributed to the enhanced M cell targeting and 
transcytosis ability of CKS9-WSC-PLGA MPs to Peyer’s patch regions. 
The high binding affinity of CKS9-WSC-PLGA MPs with the M cells to 
enter into the Peyer's patch regions of mouse small intestine was obtained 
by closed ileal loop assay and it was further confirmed by confocal laser 
scanning microscopy. These results suggest that the M cell targeting 
approach used in this study is a promising tool for targeted oral vaccine 
delivery. 
In the second approach, oral administration of live probiotics as antigen 
delivery vectors was studied as a promising approach in vaccine 
development. However, the low survival of probiotics in the gastrointestinal 
tract limits this approach. Therefore, the aim of this study was the 
encapsulation of probiotic expressing vaccine into 
alginate/chitosan/alginate (ACA) microcapsules (MCs) for efficient oral 
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vaccine delivery. Here, recombinant Lactobacillus plantarum 25 (LP25) 
expressing M cell homing peptide fused BmpB protein was used as a model 
probiotic. The viability of LP25 in ACA MCs was more than 65% in 
simulated gastric fluid (SGF, pH 2.0) and 75% in simulated small intestinal 
fluid (SIF, pH 7.2) up to 2 h. Encapsulated LP25 were completely released 
from ACA MCs in SIF within 12 h. When stored at room temperature (RT) 
or 4°C, the viability of LP25 in ACA MCs was higher than free LP25. 
Interestingly, the viability of LP25 in ACA MCs at 4°C for 5 weeks was 
above 58%, whereas viability of free LP25 stored at RT for 5 weeks was 
zero. After 4 weeks from the first immunization, LP25-M-BmpB-loaded 
ACA MCs induced a stronger BmpB-specific IgG and IgA production in 
mice. Collectively, these findings suggest that encapsulation of probiotic by 
ACA MCs is a promising delivery system for oral administration of 
probiotic expressing vaccine. 
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Oral vaccination offers several advantages over parenteral vaccination, 
including needle-free delivery, easy and comfortable administration, and the 
possibility of self-delivery. Most importantly, oral vaccination can induce 
both mucosal and systemic immunity, leading to the double layers of 
protective immune responses (Kunisawa J, 2007). In contrast, parenteral 
immunization primarily yields a systemic immune response. Therefore, 
effective oral vaccination could establish a first line of immunological 
defense in the intestinal tract, a major site of pathogen entry, as well as 
promote immune surveillance perhaps at other mucosal and systemic sites. 
One of the major strategies of oral vaccine is the induction of pathogen- or 
toxin-specific secretory IgA (sIgA).  
The hostile environment of the gastrointestinal tract (low pH, presence of 
digestive enzymes, and the detergent activity of bile salts) often makes it 
difficult to induce protective immune responses by oral vaccination with 
antigen alone. Additionally, effective oral delivery of antigen to the 
induction site of the mucosal immune system is made difficult by the 
significant dilution and dispersion of antigen that occurs in the lumen since 
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a total interior area of the intestinal wall is thought to be equivalent to over 
one tennis coat surface. Further, physical barriers, such as mucus and the 
tight junctions between the epithelial cells prevent the effective delivery of 
vaccine antigen. To overcome these obstacles, effort has focused on 
development of effective antigen delivery systems. The use of polymeric 
carrier presents a great opportunity to solve these problems.  
Poly(lactide-co-glycolide acid) (PLGA) as the U.S. Food and Drug 
Administration (FDA) and European Medicine Agency approved, 
biodegradable and biocompatible polymer has been commonly used for 
protection of drug from degradation and controlled release devices (Table 1). 
One of the most frequently employed techniques for the encapsulation of 
proteins into PLGA microparticles (MPs) is the double emulsion 
water-in-oil-in-water (W1/O/W2) solvent evaporation procedure as proteins 
tend to be hydrophilic macromolecules. However, the encapsulation of 
proteins into PLGA MPs presents some challenges due to aggregation of 
proteins (van de Weert et al., 2000) because the first emulsion of 
polymer/protein mixture is added dropwise to water and the organic solvent 
is evaporated.  
Alginates are natural polysaccharides derived from brown algae 
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comprising a linear chain of 1-4 linked β-D-mannuronic acid (M) and 
α-L-guluronic acid (G) residues (Table 1) (Kuo and Ma, 2001). These M 
and G residues exist within the chain as alternating (MG/GM) or 
homopolymeric (GG and MM) regions. By electrostatic interaction with 
calcium ions, the G homopolymeric blocks within alginate form an 
“egg-box” structure and cross-link the polymer to form a hydrogel monolith. 
This property that has led to the alginates being commonly used as an 
encapsulation material by the external gelation technique (Smidsrød, 1990; 
George and Abraham, 2006). These alginate microcapsules (MCs) can be 
used for the microencapsulation of probiotic bacteria, showing improved 
viability under simulated gastric conditions (Chandramouli et al., 2004). 
Although a “burst release” of large molecules at intestinal pH has been 
reported with alginate encapsulation alone, this could be reduced by coating 
with chitosan (Zhou et al., 2001). 
Chitosan is the N-deacetylated form of chitin, a mucopolysaccharide 
derived from various crustaceans and insects (Table 1) (Ravi Kumar, 2000). 
The chitosan has a 1-4 linked glucosamine structure (Shahidi et al., 1999). 
The amine residues in chitosan are mostly protonated below pH 6.5, 
making chitosan a polycation (Sorlier et al., 2001). The biodegradability 
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and biocompatibility of chitosan protect the drug from degradation and 
allow controlled release. 
 
Table 1. Characteristics of used polymers. 
 
 
In chapter I, a protein vaccine-BmpB was loaded into porous PLGA MPs 
coated with M cell homing peptide-coupled chitosan to investigate the in 
vitro and in vivo efficacy of the MPs for targeted oral delivery of BmpB as 
a SD vaccine (Table 2). 
In chapter II, a probiotic strain was developed through recombinant DNA 
technology that expresses and produces BmpB antigen fused with M cell 
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homing peptide. The probiotic was encapsulated into 
alginate/chitosan/alginate (ACA) microcapsules (MCs) and later delivered 
through oral route to evaluate the efficiency of vaccine delivery and 
immune responses (Table 2). 
 











Review of Literature 
1. Characteristics of the gastrointestinal tract 
When designing probiotics and vaccines for oral delivery systems, it is 
necessary to consider the complex physiology of the gastrointestinal (GI) 
tract (Figure 1). Typically the release of the probiotics and vaccines will be 
triggered by degradation, disintegration or dissolution of the formulations 
(Gombotz and Wee, 2012). Along the GI tract there are various possible 
methods based on pH, time, peristaltic pressures and bacterial fermentation 
for delivery. 
After ingestion, probiotics and vaccines will pass quickly through the 
oesophagus around 10-14 s (Aulton and Taylor, 2013) and reach the 
stomach; this is the point at which the greatest viability loss of probiotics 
and vaccines is considered due to high levels of acid. The pH values of the 
stomach have been reported to lie within pH 1-2.5 for uncontrolled groups 
(Evans et al., 1988) whereas it may be as high as pH 5 for fed patients 
(Fordtran and Walsh, 1973). Gastric emptying time is also highly variable 
(McConnell et al., 2008), and is often reported as between 5 min and 2 
hours; however, the half gastric emptying time using 13C breath tests has 
been estimated to be around 80.5 min (Hellmig et al., 2006). The emptying 
of stomach contents is usually a result of peristaltic action known as the 
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migrating myoelectric complex (Janssens et al., 1983), whilst the pyloric 
sphincter ensures retention of large, insufficiently digested contents (Aulton 
and Taylor, 2013). As a result, smaller particles will be retained for a short 
time. The stomach has a fluid capacity of up to approximately 1.5 L but 
usually contains only 50 ml in a fasted state (Aulton and Taylor, 2013). In 
addition to acid, the stomach also contains pepsin, a proteolytic enzyme, 
which breaks down proteins. Pepsin is produced by the auto-catalytic 
cleavage of its precursor zymogen, pepsinogen, at the low pH of the 
stomach. 
 
Figure 1. Characteristics of the GI tract, showing the pH at the different parts 
(Cook et al., 2012). 
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After passage through the stomach, the probiotics and vaccines will enter 
the small intestine, which has been reported in one study to be 3.2±1.6 h 
(Davis et al., 1986) and in another ranging from 0.5 to 9.5 h (Coupe et al., 
1991). Significant variation in small intestinal transit time were observed 
upon repeated experimentation for a single patient (McConnell et al., 2008), 
indicating a large variability within individual subjects. The pH of the small 
intestine has been estimated to lie in the range of pH 6.15-7.35 in the 
proximal region, rising to pH 6.80-7.88 in the distal small intestine. After 
passage through the small intestine, the probiotics and vaccines will reach 
the large intestine at which point the pH lowers slightly to pH 5.26-6.72 in 
the ascending colon, and pH 5.20-7.02 in the descending colon (Press et al., 
1998). The transit time of pharmaceuticals in the large intestine is highly 
variable, with a range of 6-32 h typically reported (Coupe et al., 1991), but 
longer time also have been noted (Sathyan et al., 2000). As the probiotics 
and vaccines descend down the GI tract, the relative quantity of liquid 
present will decrease as the contents are compacted into feces (McConnell 
et al., 2008).  
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2. Characteristics of the intestinal M cell 
M cells are specialised epithelial cells mainly found in the 
follicle-associated epithelium (FAE) overlying Peyer’s patches (PPs) and 
other lymphoid aggregates (Figure 2) (Clark et al., 2001).  These cells are 
distinguished from surrounding epithelial cells by the absence of the surface 
microvilli that are characteristic of intestinal epithelial cells. Instead, the 
apical membrane of the M cell has a microfold (or membranous) 
topography, hence named as M cell. Although M cells also form tight 
junctions with adjacent cells to maintain the epithelial barrier, they have a 
deeply invaginated basolateral membrane which contains infiltrating 
lymphocytes (Owen and Jones, 1974). Consequently, once antigens are 
transcytosed by the M cell, they can quickly move to the basolateral 
membrane to reach and interact with underlying lymphoid aggregates 
(Owen, 1977). 
The M cell may be the preferred cell type for mucosally targeted vaccine 
delivery, but it should be mentioned that other cell types at mucosal 
surfaces have some antigen sampling ability. In addition, dendritic cells, the 
professional antigen-presenting cells, can directly sample antigens from 
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mucosal surfaces (Kaiserlian and Etchart, 1999). However, the M cell is 
still most attractive for targeted vaccine delivery because of its high 
transcytotic activity at the FAE. Although villous M cells located outside 
the FAE have also been identified (Jang et al., 2004), the M cells of the FAE 
remain the primary vehicles for antigen sampling and subsequent induction 
of mucosal immune responses (Man et al., 2004). As such, the FAE has 
lower amounts of secretory IgA (sIgA) and mucus and the M cells of the 
FAE have a much thinner surface glycocalyx as compared to other intestinal 
epithelial sites, allowing for easier antigen sampling (Frey et al., 1996; 




Figure 2. Schematic transverse sections of a PPs lymphoid follicle and 
overlying FAE, depicting M cell transport of particulate delivery vehicles. The 
general structure of intestinal organised mucosa-associated lymphoid tissues is 
represented by the schematic transverse section of a PPs lymphoid follicle and 
associated structures in (A). The lymphoid follicle is situated beneath a dome 
area which protrudes into the gut lumen between villi and which is covered by 
the FAE. This epithelium is characterised by the presence of specialised antigen 
sampling M cells (depicted in B) (Clark et al., 2001). 
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3. Oral delivery of vaccine 
Vaccination is the best and most effective strategy to make defense 
against many diseases (Faulk and Dolinoy, 2011) and have been known for 
hundreds of years in various forms. For example, during the period of 
Middle Ages, in China it was found that inhaling a powder made from 
smallpox scabs could protect from future infection and provided immune 
responses. Historically, the first clear example of vaccination, which 
remains among the most dramatic ever recorded, was Edward Jenner’s 
successful vaccination against smallpox. Jenner who was an English 
physician observed that the milkmaids never contracted the more serious 
smallpox who had recovered from cowpox. On this standpoint of 
observation, he injected the material from a cowpox pustule into the arm of 
an 8-year old boy. After then he intentionally infected the boy with 
smallpox and found that the disease did not develop. This revolutionary 
invention by Jenner on vaccination was published in 1798. The concept 
received the widespread acceptances for inducing immunity to infectious 
diseases. From that time, therefore, vaccination considers the most effective 
way for preventing infection (Abbas et al., 1994). 
Almost all of the vaccines are administered parentally by intravenous, 
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intramuscular or subcutaneous injections (Mitragotri, 2005; Giudice and 
Campbell, 2006). Parenteral administration of vaccine is associated with 
several problems such as the injection is painful, need of high patient 
compliances, have injection risk factors, need of trained personnel to 
administer and most importantly, it provides short half-lives of drugs at the 
target site of application (Quan et al., 2007). To avoid these-mentioned 
problems associated with parenteral administration of vaccine, scientists 
have been extensively worked for many years to develop a suitable delivery 
system for effective vaccination. 
Oral vaccination is the most attractive and acceptable administrative 
route of vaccine delivery (Ahire et al., 2007). Oral delivery of vaccine is 
easy to administer, provides patient compliances, avoids the risk factors 
associated with parenteral administration and able to induce both local and 
systemic immune responses. Despite of having various advantages 
associated with oral vaccination, however, it is the most challenging and 
difficult field in the research arena due to several important factors such as 
degradation of antigen in stomach acidic environment, presence of 
degradative enzymes and low uptake by the gut-associated lymphoid tissues 
(GALT) which is the most important target in terms of oral vaccination. 
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Hence, due to afore-mentioned problems, there is a considerable interest in 
the development of novel delivery systems for oral administration of 
vaccine which can be used to package and deliver a range of antigen against 
important pathogens. Because of the safety talk, it will be desirable if the 
delivery system is based on non-living carrier systems rather than modified 
bacterial or viral vectors (O'Hagan, 1998). 
An orally administered antigen induces immune responses at GALT 
which have a largest portion consists of the PPs (Lavelle et al., 1995). The 
PPs are the main target for the oral vaccines which are present in lower 
ileum (Van der Lubben et al., 2001). The polymeric microparticles (MPs) 
offer significant potential to develop suitable carrier systems for orally 
administered vaccines. A wide range of polymers can be used to prepare the 
polymeric MPs which can be designed to protect the entrapped vaccines 
against degradation and subsequently target the vaccines into the GALT for 
uptake by the PPs. The antigen incorporated into polymeric 
microparticulate system induces antigen-specific immune response to a 
greater extent than an antigen in the soluble form. The polymeric particles 
incorporated with antigens can protect them from degradation by the acidic 
environment of the stomach, proteolytic activity of degradative enzymes 
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and bile salts in the gut and subsequently enhances the antigen uptake via 
the phagocytic M cells present in PPs (Tabata et al., 1996). When the MPs 
transport and reach to the dome of the PPs, they are degraded and the 
incorporated vaccines are released into the lymphoid tissues. Stimulation 
induced by the antigen in PPs which is then presented to B and T cells. The 
presentation of antigen-specific stimulation to B and T cells accelerates B 
and T cells proliferation and these cells subsequently leave the PPs via 
efferent lymphatics and participate in the systemic circulation through the 
thoracic duct (O'Hagan et al., 1989; O'hagan et al., 1991). Along with the 
systemic antibody responses following oral administration of polymeric 
MPs incorporated with antigen, it has also been reported that they can also 
effectively induce mucosal antibody responses which is essential for oral 
vaccine delivery (Chang and Prakash, 1998; Young, 2008). 
4. Oral delivery of probiotics 
Enormous commercial and scientific research interest have been paid to 
lactic acid bacteria because of their tremendous health benefits in the 
gastrointestinal (GI) tract. They are considered good and friendly bacteria 
which can inhibit and reduce numbers of potentially harmful bacteria from 
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the intestine (Prakash and Chang, 1996). The use of lactic acid bacteria in 
therapeutic purpose have been received considerable interest for treating 
several important diseases like cancer, kidney failure uremia, inflammatory 
bowel diseases (IBD), hypercholesteremia and many others (Anderson and 
Gilliland, 1999; McIntosh et al., 1999; Lin et al., 2008). Lactic acid bacteria 
also play very important role for the production of various food products 
such as yogurt, cheese, fermented milk which also have beneficial health 
effects. Some lactic acid bacterial strains have shown that they can suppress 
intestinal tumors induced by chemical mutagens. They also have facilitated 
several other beneficial effects such as lowering cholesterol, 
immunomodulatory, anticarcinogenic and antimicrobial action (Reddy et al., 
1973; Singh et al., 1997; Fuller and Perdigon, 2000). In 1973, Reddy et al. 
reported that the feeding of yogurt inhibited the growth of Ehrlich ascites 
tumor in the peritoneal cavity (Reddy et al., 1973). Perdigon et al. have also 
extensively investigated the lactic acid bacteria for their therapeutic 
applications (Fuller and Perdigon, 2000). They demonstrated that feeding of 
lactic acid bacteria and yogurt augmented systemic as well as local immune 
responses. They further reported that the feeding of L. casei and L. 
acidophilus fermented milk inhibited the GI infection occurred by 
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Salmonella typhimurium and Escherichia coli. They suggested that these 
biological activities were a result of the immunomodulating abilities of the 
lactic acid bacteria and their fermented food products. 
It is important to know that the live bacterial cells must be delivered to the 
intestine alive through oral administration to exert the beneficial health 
effects. From various investigations, there are considerable evidences to 
support the fact that oral administration is essential for lactobacillus 
delivery in order to induce therapeutic effects; however, several obstacles 
have made this novel approach as a challenging field in the scientific area. 
When live bacterial cells are intended to deliver orally to the target site of 
intestine, they must be protected from the stomach acidic environment, bile 
acids and the degradative enzymes; otherwise they will be denatured or 
degraded (Siuta-Cruce, 2001). All these factors cause their poor survival 
and stability before their arrival to the target site alive. Therefore, an 
effective carrier system is necessary for their oral delivery to induce proper 
therapeutic applications. Microencapsulation technique provides suitable 
carrier system for live bacterial cells and has been received considerable 
attention for protecting them from afore-mentioned unfavorable 
environments and to exert their potential therapeutic applications.  
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Chapter 1.  Targeted oral delivery of BmpB vaccine 
using porous PLGA microparticles coated with M cell 
homing peptide-coupled chitosan 
1. Introduction 
Oral vaccines offer significant advantages over needle-based vaccines, 
such as easy handling, high patient compliance, low cost of production and 
induction of mucosal immunity (Islam et al., 2012), yet oral vaccination has 
several defects, such as degradation of the vaccine in the gastrointestinal 
(GI) tract due to the low pH and enzymes in the stomach, the impermeable 
GI epithelium as a physical barrier and inefficient targeting to the action site, 
resulting in a low bioavailability (Renukuntla et al., 2013). Therefore, the 
physicochemical properties and biological restrictions of the vaccine need 
to be considered for the development of an effective delivery system for 
oral vaccines (Mahato et al., 2003).  
Moreover, the vaccine should reach M cells to stimulate adequate 
immune responses after oral delivery. The M cells, specifically located on 
the follicle-associated epithelium (FAE) in Peyer’s patch (PP) of the gut, 
possess a unique property to take up and deliver vaccines from the enteric 
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environment into the PP via transcytosis (Yoo et al., 2010). Vaccines 
delivered through the M cells in the PP, referred to as gut-associated 
lymphoid tissues (GALT), facilitate the induction of vaccine-specific 
immune responses by activating antigen-presenting cells and lymphocytes 
(Neutra et al., 1996; Ann Clark et al., 2001). 
Undoubtedly, the receptor-mediated targeting of M cells would be an 
approach of oral vaccination (Foxwell et al., 2007), but the lack of 
differentiation of M cell receptors from the adjacent enterocytes hindered 
the M cell targeting oral delivery (Tyrer et al., 2006). Recently, we 
identified a CKSTHPLSC (CKS9) peptide by phage display which showed 
high affinity towards M cells (Yoo et al., 2010). The peptide facilitated the 
transport of chitosan nanoparticles across the M cell to enter the FAE in the 
PP demonstrating CKS9 as a potential M cell-targeting ligand. 
In recent years, the use of porous materials has been greatly extended in 
bio-related fields (Ariga et al., 2012; Vilela et al., 2012; Hartmann and 
Kostrov, 2013). Particularly in drug delivery system, the porous 
biodegradable polymeric microparticles (MPs) are applied as protein and 
peptide carriers for oral delivery (Hanes et al., 1997; Mi et al., 2003; 
Jaklenec et al., 2008; Lee and Yoo, 2008). These porous MPs have attracted 
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much attention because of their protection of proteins from degradation and 
their satisfactory releasing behavior (Edwards, 1997). While the pore sizes 
in MPs can be adjusted to control the release of the molecules, chemical 
modifications of the surfaces may indeed offer targeted delivery. 
Swine dysentery (SD) is a contagious mucohemorrhagic disease of pigs 
that is caused by pathogenic intestinal spirochete Brachyspira 
hyodysenteriae (Edwards, 1997). Several attempts have been made to use 
either attenuated or genetically modified live avirulent vaccines for SD 
(Stanton et al., 1999). But, a recent approach to prevent pigs from SD used 
an outer envelope lipoprotein of B. hyodysenteriae (BmpB) and confirmed 
the protection of pigs from SD by vaccination with the recombinant BmpB 
(Lee et al., 2000). 
In this study, we loaded BmpB into porous poly(lactic-co-glycolic acid) 
(PLGA) MPs coated with M cell homing peptide-coupled chitosan and 
investigated the in vitro and in vivo efficacy of the MPs for targeted oral 
delivery of BmpB as a SD vaccine. 
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2. Materials and Methods 
1). Materials 
Carboxyl acid-terminated PLGA (lactic acid/glycolic acid: 50/50; Mw = 
17kDa) was purchased from Purac Biochem (Gorinchem, Holland). Sodium 
oleate was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, 
Japan). CKS9 (CKSTHPLSC) was chemically synthesized by Anygen 
(Gwangju, Korea). Water-soluble chitosan (WSC, MW = 9,600; degree of 
deacetylation = 91.8%) was kindly provided by Prof. Nah (Sunchon 
National University, Korea). DifcoTM LB broth was purchased from BD 
(Sparks, MD, USA). Rabbit anti-BmpB antibody was purchased from 
AbClon (Seoul, Korea). 3,3’,5,5’-tetramethyl benzidine (TMB); horseradish 
peroxidase (HRP)-conjugated goat anti-mouse IgA, IgG, IgG1 and IgG2a; 
and HRP-conjugated goat anti-rabbit IgG antibody were purchased from 
Santa Cruz Biotechnology (Dallas, TX, USA). Bovine serum albumin 
(BSA), coumarin 6, poly(vinylalcohol) (PVA), N-hydroxysuccinimide 
(NHS), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
(EDC), 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI), 
tetramethylrhodamine isothiocyanate (TRITC)-conjugated Ulex Europaeus 
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Agglutinin I lectin (UEA-I), and other chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). 
2). Preparation of BmpB protein 
E. coli harboring the gene encoding for the BmpB protein was inoculated 
into LB broth and incubated at 37°C with shaking at 100rpm for 4 h. The 
culture was induced with IPTG (1 mM) and incubated for an additional 12 h. 
E. coli cells were collected by centrifugation and washed twice with 
phosphate buffered saline (PBS). The cells were suspended in His-binding 
buffer for cell lysis by sonication to collect the expressed His-tagged 
protein. The protein was separated from the cell debris by centrifugation at 
12,000 rpm for 30 min. The protein was finally purified according to the 
manufacturer’s instructions (Clontech). The purity of the protein was 
assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). The collected protein was dialyzed overnight against water 
(pH 7.9) at 4°C. The purified protein was freeze dried and maintained at 
-20°C until use. 
3). Preparation of CKS9-conjugated chitosan 
CKS9-conjugated water-soluble chitosan (CKS9-WSC) was prepared by 
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the conjugation of WSC with CKS9 using NHS/EDC coupling agents 
following a previously described method (Yoo et al., 2010). The synthetic 
scheme is shown in Figure 1. The composition of the CKS9-WSC was 
determined by 1H NMR spectroscopy (Avance 600, Bruker, Germany) and 
Fourier transform infrared spectrometer (FT-IR; Nicolet 6700, Thermo 
Fisher Scientific Inc., Waltham, MA, USA). 
 
 
Figure 1. Schematic diagram for the synthesis of CKS9-WSC. 
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4). Preparation of porous PLGA MPs 
4-1). Preparation of BmpB-loaded porous PLGA MPs 
(BmpB-PLGA MPs) 
The BmpB-PLGA MPs were prepared using a water-in-oil-in-water 
(W1/O/W2) emulsion solvent evaporation method, as previously described 
(Sun et al., 2009) with some modifications. First, 7.5 mg of BmpB was 
dissolved in 100 µl of distilled water, and a sodium oleate solution was 
prepared in 200 µl of distilled water, which was used as the W1 phase. 
PLGA (0.12 g) was dissolved in 2 ml methylene chloride (O phase) and 
emulsified with the W1 phase by sonication on ice to form the stable initial 
emulsion (W1/O). Second, the resultant emulsion was added drop wise into 
40 ml of a 5% (w/v) PVA solution and emulsified for 2 h at a predetermined 
speed using a direct driven digital stirrer, resulting in the formation of the 
W1/O/W2 emulsion. Third, 50 ml of a 6% (v/v) isopropanol solution was 
poured into the double emulsion to extract the organic solvent and then 
stirred for approximately 4 h in a fuming cupboard. After the evaporation of 
the organic solvent, the hardened MPs were collected by centrifugation. The 
resultant MPs were rinsed with distilled water and collected by 
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centrifugation. The MPs were dried by freeze drying. Drug free PLGA MPs 
were also prepared as a control using the same procedure. 
4-2). Preparation of coumarin-6-loaded porous PLGA MPs 
(coumarin-6-PLGA MPs) 
In case ofcoumarin-6-PLGA MPs, a sodium oleate solution prepared in 
200 µl of distilled water (W1 phase) was emulsified with 0.12 g PLGA 
along with 7.5 mg of coumarin-6 dissolved in 2 ml of methylene chloride 
(O phase) to form the stable initial emulsion (W1/O). Further processes 
were followed similar to the preparation of the BmpB-PLGA MPs, as 
described above. 
4-3). Preparation of CKS9-WSC and WSC coated BmpB- or 
coumarin-6-PLGA MPs 
The surface of the PLGA MPs was coated with CKS9-WSC or WSC. 
Briefly, 10 mg of BmpB- or coumarin-6-PLGA MPs was dispersed into 2 
ml of 0.05 M MES buffer (pH 5.6) containing 1% (w/v) WSC or 
CKS9-WSC with stirring for approximately about 3 h. MPs were collected 
by centrifugation and freeze drying. 
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5). Morphology observations and particle size measurements 
The surface and cross-section morphologies of the MPs were observed 
using a field-emission scanning electron microscope (FE-SEM; Supra 55VP; 
Carl Zeiss, Oberkochen, Germany). Pore size was manually calculated from 
the SEM images. In addition, the internal porosity of PLGA MPs was 
approximately obtained from manual calculation, based on the 
pore-occupied area over the entire cross-sectional area of PLGA MPs as 
previously described (Bae et al., 2009). The particle sizes were measured 
using DLS-7000 (Otsuka Electronics. Ltd., Tokyo, Japan). 
6). Determination of loading content and loading efficiency 
Loading content was determined as follows. The MPs were dispersed 
into 3 ml of 0.1 M NaOH containing 5% (w/v) SDS (Corrigan and Li, 
2009). The suspension was incubated in a water bath at 60 °C for 1 h. 
Following centrifugation, 1 ml of the supernatant was withdrawn for 
micro-BCA analysis. The loading efficiency of the BmpB was determined 
using the ratio of the actual amount of loaded BmpB over the total amount 
of BmpB used for the preparation of the MPs.  
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7). Release of BmpB from the BmpB-PLGA or BmpB-WSC- 
PLGA MPs 
The in vitro release of BmpB from BmpB-PLGA or BmpB-WSC-PLGA 
MPs was determined as follows. The BmpB-loaded MPs, separated from a 
1 ml suspension by centrifugation, were placed into 1.5 ml Eppendorf tubes 
with 1 ml of PBS (pH 7.4 or pH 1.2) for 48 h at 100 rpm (37 °C) in a 
shaking incubator. A 1 ml aliquot was withdrawn and replaced with an 
equal volume of release medium at a predetermined time, and the amount of 
BmpB released was measured using the micro-BCA assay method. 
8). Structural integrity of the BmpB antigen 
The integrity of protein antigens before and after encapsulation in MPs 
was assessed by SDS-PAGE and Western blot as previously described 
(Florindo et al., 2009) with some modifications. While rabbit serum 
anti-BmpB antibody was used as primary antibody, HRP-conjugated goat 
anti-rabbit IgG antibody was used as secondary antibody. 
9). Validation of targeting property of CKS9-WSC-PLGA MPs 
To validate the targeting property of the CKS9-WSC-PLGA MPs to the 
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PP, the closed ileal loop assay was conducted and assessed using confocal 
laser scanning microscopy (CLSM; Carl Zeiss LSM710, Carl Zeiss, Inc.) as 
previously described (Yoo et al., 2010) with slight modifications. The 
coumarin-6-loaded MPs (1 mg/ml) were injected into the closed ileal loops. 
After 1 h of retention, the closed ileal loop was excised and washed with 
cold PBS three times. The tissue samples were then fixed with 10% (v/v) 
formalin and freeze-sectioned. Sections of the samples were stained using 
TRITC-conjugated UEA-1 and DAPI. 
10). Oral immunization 
Female BALB/c mice were obtained from Samtako, Co. Ltd. (Osan, 
Korea), and used at 8 weeks of age. The animals were maintained under 
standard pathogen-free conditions and provided with free access to food 
and water during the experiments. All animals were maintained and used in 
accordance with the guidelines for the care and use of laboratory animals 
(Seoul National University). The mice were divided into 5 cohorts (5 mice 
per cohort). Each mouse was given an oral gavage of 200 µl PBS containing 
an amount equivalent to 200 µg of BmpB either in BmpB solution, 
BmpB-PLGA, BmpB-WSC-PLGA, BmpB-CKS9-WSC-PLGA MPs or 
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control (PBS). All groups received a total of 6 doses of the vaccines (or 
control) on days 0, 1, 7, 8, 14 and 15 (Figure 2). To assess immune 
responses, serum tail vein blood and feces samples were taken at days 0, 14, 
21 and 28 (prior to the first immunization). The blood samples were 
centrifuged for 10 min at 5,000 rpm, and the serum was collected and stored 
at -70°C until analysis for IgG, IgG1 and IgG2a titers. Five fecal pellets, 
selected randomly from each mouse, were vortexed with 500 µl of PBS. 
After 30 min of incubation at room temperature, the fecal samples were 
centrifuged at 6,000 rpm for 15 min. The supernatants were collected and 
analyzed for the presence of antigen-specific IgA as previously described 
(Enioutina et al., 1999). Finally, the small intestines (3 cm) of the mice were 
immediately collected after sacrifice. The intestines were homogenized in 
500 µl of ice-cold PBS. Tissues were removed by centrifugation (10,000 
rpm, 10 min and 4 °C), and the supernatants were collected and stored at 
-70 °C until analysis for IgA titers. 
 
 
Figure 2. Schematic representation of the oral immunization protocol. 
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11). Evaluation of antibody production 
The induction of BmpB-specific antibodies was measured by 
enzyme-linked immunosorbent assays (ELISA). ELISA plates were coated 
with BmpB (25 µg/ml) and incubated overnight (4 °C). The plates were 
then washed and blocked with 1% (w/v) bovine serum albumin. Serially 
diluted samples (100 µl/well) were then added, and the mixtures were 
incubated for 2 h. Following washes with PBS containing 0.1% Tween 20, 
each sample was appropriately treated with HRP-conjugated goat 
anti-mouse IgG, IgG1 and IgG2a antibody (1:5,000) or goat anti-mouse IgA 
antibody (1:2,000). After 1 h of incubation and subsequent washings, the 
samples were treated with TMB substrate buffer, and the reaction was 
stopped after 15 min with 50 µl of 2 M H2SO4. The optical densities (OD) 
of the samples were measured at 450 nm using an Infinite 200 PRO 
multimode reader (Tecan, Switzerland). 
12). Statistical analyses 
All results are expressed as the mean ± SD. Differences between means 
were tested for statistical significance using a one-way analysis of variance 
(ANOVA) and post hoc least significance tests. SPSS 13 program (SPSS®, 
Chicago, USA) was used for all statistical analyses.  
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3. Results and Discussion 
1). Characterization of porous PLGA MPs coated with M cell 
homing peptide-coupled chitosan 
To prepare M cell homing peptide-coupled chitosan, first, the CKS9 
peptide was coupled with WSC through an amide linkage between the 
carboxylic acid in the C-terminal of the CKS9 peptide and the amino 
groups in the WSC using EDC/NHS as activation agents as shown in Figure 
1. The introduction of the CKS9 peptide to WSC was confirmed by 1H 
NMR (Figure 3) and FT-IR (Figure 4). The characteristic peaks at 7.06 and 
7.78 ppm in 1H NMR were assigned to the two protons of the imidazole 
ring in the histidine of the CKS9 peptide. However, the other proton peaks 
of the CKS9 peptide were not distinguished due to the overlap of WSC 
peaks in the spectra. The degree of substitution of the CKS9 in the 
CKS9-WSC was estimated by calculating the integral ratio between the two 
protons of imidazole ring of histidine in CKS9 and three protons of the 
acetyl group of WSC appeared at 2.1 ppm. The composition of the CKS9 in 








Figure 4. FT-IR spectra of water-soluble chitosan (WSC) (A), CKS9 (B), and 
CKS9-WSC (C). The FT-IR spectrum of WSC shows some characteristic 
absorption bands at about 3437 cm-1 (νN-H and νO-H) 1632 (ν-CONH-) and 
1060 cm-1 (νC-O-C). While the characteristic peak of chitosan at 1060 cm-1 
(νC-O-C) is also observed in the spectrum of CKS9-WSC,the characteristic 




Porous PLGA MPs were prepared using the conventional double 
emulsion method with sodium oleate as a porogen. As shown in Figure 5, 
the PLGA MPs have a smooth surface and spherical shape with a slight 
porosity at the surface and larger inner pores. The morphologies of the 
PLGA MPs were not significantly altered after loading BmpB into the MPs. 
The porous PLGA MPs were coated with CKS9-coupled WSC through an 
ionic interaction between the carboxylic groups of the outer PLGA MPs and 
the amino groups of the CKS9-coupled WSC. In addition, the morphologies 
and porosities of the PLGA MPs were not significantly altered after coating 
with WSC. The pores were well interconnected inside the foam structure, 
thus enhancing the surface area to volume ratio available for drug diffusion 
and polymer degradation. The pore size varied from about 200 nm to 1000 
nm. PLGA MPs contains about 70% internal porosity as observed by 
manual calculation, based on the pore-occupied area over the entire 
cross-sectional area of MPs. 
The particle size distributions of the PLGA MPs (A), BmpB-loaded 
PLGA MPs (BmpB-PLGA MPs) (B), BmpB-loaded WSC-coated PLGA 
MPs (BmpB-WSC- PLGA MPs) (C), and BmpB-loaded M cell homing 
peptide-coupled WSC-coated PLGA MPs (BmpB-CKS9-WSC-PLGA MPs) 
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(D) are shown in Figure 6. The particle size of the PLGA was 
approximately 3.07 µm with a unimodal particle distribution, but slightly 
increased after loading BmpB into the PLGA and WSC-PLGA MPs. The 
particle shape and size can be manipulated to maximize interactions at the 
cellular level. Phagocytotic cells such as macrophages and M cells are able 
to ingest micron-sized particles with diameters between 1 and 5 µm, and 
therefore, targeting these cells in the intestinal or respiratory tract allows the 
use of larger particles (van der Lubben et al., 2001; Bhavsar and Amiji, 
2007) 
 
Figure 5. FE-SEM image of the surface and internal morphologies of the 
PLGA MPs (A), WSC-PLGA MPs (B), BmpB-PLGA MPs (C) and 




Figure 6. Particle size distributions of the PLGA MPs (A), WSC-PLGA MPs 
(B), BmpB-PLGA MPs (C) and BmpB-WSC-PLGA MPs (D). 
 
2). BmpB loading into PLGA and WSC-PLGA MPs 
The BmpB content and loading efficiency of BmpB in the BmpB-PLGA 
and BmpB-WSC-PLGA MPs are shown in Table 1. The loading content and 
loading efficiency of BmpB in the BmpB-PLGA MPs were 12.3% and 60.9% 
by weight respectively, whereas the loading content and loading efficiency 
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of BmpB in the BmpB-WSC-PLGA MPs were 10.4% and 57.6% by weight 
respectively, suggesting that there were not significant differences in the 
loading content and loading efficiency of BmpB between the PLGA and 
WSC-PLGA MPs. Porous PLGA MPs typically display a low drug loading 
efficiency and relatively rapid release profile due to their large surface area 
(Arnold et al., 2007; Giovagnoli et al., 2007; Bae et al., 2009; Lee et al., 
2010; Kim et al., 2012). 
 
Table 1. Loading content and loading efficiency of BmpB loaded PLGA MPs 
 
MPs Loading content (%) Loading efficiency (%) 
BmpB-PLGA MPs 12.28 ± 2.45 60.93 ± 2.31 
BmpB-WSC-PLGA MPs 10.36 ± 1.77 57.64 ± 3.13 
BmpB-CKS9-WSC-PLGA MPs 10.13 ± 2.08 56.59 ± 3.07 
 
3). BmpB release from the BmpB-PLGA and BmpB-WSC-PLGA 
MPs 
In vitro BmpB release from the BmpB-loaded MPs was performed in 
PBS incubated at 37°C with 100 rpm and the amount of released BmpB was 
evaluated by micro-BCA assay. The release of BmpB from the 
BmpB-PLGA and BmpB-WSC- PLGA MPs at pH 1.2 and pH 7.2 are 
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shown in Figure 7. The results indicated that the release of BmpB from the 
BmpB-PLGA and BmpB-WSC-PLGA MPs was higher at pH 7.2 compared 
to pH 1.2, likely due to the greater swelling of the PLGA MPs at pH 7.2 
compared to pH 1.2. Notably, the burst effect of BmpB release from the 
BmpB-PLGA MPs at pH 7.2 was obtained within 30 min. In addition, the 
release of BmpB from the BmpB-PLGA MPs at pH 1.2 and pH 7.2 
decreased after coating the PLGA MPs with WSC.  
Unlike low molecular weight drugs, proteins possess secondary, tertiary, 
and even quaternary structures with labile bonds between the side chains of 
chemically reactive groups. Disruption of these structures or modifications 
of their side chains can lead to loss of protein activity (Kammona and 
Kiparissides, 2012). During the loading of vaccine into the MPs, the 
vaccine’s stability is very important for retaining its immune activity. 
Therefore, the structural integrity of the BmpB released from the BmpB- 
PLGA MPs was evaluated by SDS-PAGE (Figure 8 A) and Western blot 
(Figure 8 B) to evaluate BmpB stability. As shown in Figure 8 (A and B), 
the BmpB release from the BmpB-PLGA, BmpB-WSC-PLGA and 
BmpB-CKS-WSC-PLGA MPs was similar to native BmpB, indicating that 







Figure 7. BmpB release profiles from the PLGA and WSC-PLGA MPs at 







Figure 8.  Evaluation of the structural integrity of BmpB released from the 
BmpB-PLGA MPs by SDS-PAGE (A) and Western blot (B). Lane 1: marker, 
Lane 2: native BmpB, Lane 3: drug-free PLGA MPs, Lane 4: BmpB release 
from PLGA MPs, Lane 5: BmpB release from WSC-PLGA MPs and Lane 6: 




4). Targeting properties of the CKS9-WSC-PLGA MPs 
The low potency of the oral vaccine might be due to several challenges, 
including antigen degradation by proteolylic enzymes, the low dose of 
antigen absorbed and not actively directing antigens to M cells (Azizi et al., 
2010). To overcome these problems, an oral delivery system that would 
protect antigens and specifically target M cells is necessary. To evaluate the 
targeting ability of the MPs to PPs in vivo, the coumarin-6 loaded MPs, 
namely coumarin-6-loaded PLGA (coumarin-6-PLGA), coumarin-6- loaded 
WSC-PLGA (coumarin-6-WSC-PLGA), and coumarin-6-loaded 
CKS9-WSC- PLGA (coumarin-6- CKS9-WSC-PLGA) MPs were injected 
into the closed ileal loops and the in vivo co-localization of the MPs in the 
PP region were monitored 1 h later by CLSM (Figure 9). While there were 
no green signals in the PBS group, other PLGA MPs showed significant 
green signals in the PP region. The figure clearly showed the co-localization 
of the coumarin-6-CKS9-WSC-PLGA MPs in the PP was the highest 
among the MPs used. These results strongly suggested that the introduction 
of CKS9 into the WSC increased the affinity of PLGA MPs with the M 
cells to enter to the PP in the mouse small intestinal tract compared with the 
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PLGA and WSC-PLGA MPs. Considering the effect of micro- or 
nanocarrier surface charges on its cellular uptake rate, it has been postulated 
that a positive zeta potential is beneficial for M cell transport because the M 
cell membrane is negatively charged. Therefore, positively charged chitosan 
was used to coat the PLGA MPs. However, mucus and epithelial cells carry 
a negative charge as well, making electrostatic interactions with the micro- 
or nanocarriers very unspecific (Slutter et al., 2008). To overcome the 
unspecific interactions, the PLGA MPs were decorated with M cell 
targeting peptide conjugated chitosan. As a consequence, the 
CKS9-WSC-PLGA MPs (the green signals) were more localized within the 
FAE layer of the PP (the red signals) on which the M cells were abundant 
(Figure 9 d) compared to the PLGA (Figure 9 b) or WSC-PLGA MPs 





Figure 9. In vivo localization of fluorescent CKS9-WSC-PLGA MPs on the 
mice Peyer’s patch region 1 h after an injection into closed ileal loops; (a) PBS, 
(b) PLGA MPs, (c) WSC-PLGA MPs and (d) CKS9-WSC-PLGA MPs. 
 
5). Immune responses in vivo 
The induction of mucosal and systemic immune responses after oral 
delivery initiates from mucosal sites. At the intestinal mucosal sites, 
particulate antigens (BmpB) are transported by M cells and delivered to 
sub-mucosa. Subsequently, antigen-presenting cells process and present the 
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antigen to T-cells in the adjacent mucosal lymph nodes. Next, activated 
T-cells that are stimulated by antigen-presenting cells induce IgG and 
IgA-committed B-cell development in the germinal center of the 
mucosal-associated lymphoid tissue. Finally, activated B-cells will migrate 
via the draining lymph nodes and the thoracic duct to the systemic 
circulation and other mucosal effector sites, where IgG and IgA-committed 
B-cells differentiate to antibody secreting plasma cells, which produce IgG 




Figure 10 . Schematic representation of induction of both mucosal and 
systemic immune responses at the mucosal-associated lymphoid tissue in the 





The main goal of this work was to investigate the immune responses of 
the BmpB released from the BmpB-CKS9-WSC-PLGA MPs after oral 
delivery. The local production of sIgA would establish a first defense line at 
the mucosal surface, blocking the pathogen adhesion. To assess the success 
of the mucosal immunization, the local sIgA levels present in the intestine 
and excreta were determined. The mice treated with BmpB-WSC-PLGA 
showed higher titers of anti-BmpB sIgA antibody responses in feces 
compared with those treated with the BmpB solution or BmpB-PLGA MPs 
(Figure 11 A). In particular, mice treated with the BmpB-CKS9- 
WSC-PLGA MPs 4 weeks after their first immunization displayed 5.7- and 
7.9-fold higher titers compared to those treated with the BmpB solution or 
BmpB-PLGA MPs, respectively. The anti-BmpB sIgA antibody responses 
in the intestine after the immunization are shown in Figure 11 B. The mice 
treated with the BmpB-WSC- PLGA MPs displayed higher titers compared 
to those treated with the BmpB solution or BmpB-PLGA MPs, showing a 
similar tendency as in feces. Four weeks after the first immunization, the 
sIgA titers of the mice treated with the BmpB-CKS9-WSC- PLGA MPs 
were 24.7- and 18.5-fold higher compared to those treated with the BmpB 
solution and BmpB-PLGA MPs, respectively. Humoral immunity at the 
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mucosal surface is principally mediated by sIgA antibodies, which are the 
predominant immunoglobulin class in external human secretions. Although 
sIgA is the predominant humoral defense mechanism at mucosal surfaces, 
locally produced IgG and serum-derived IgG can also significantly 
contribute to immune defense (Holmgren and Czerkinsky, 2005). The 
anti-BmpB IgG antibody responses in serum after immunization are shown 
in Figure 11 C. The mice treated with BmpB-WSC- PLGA displayed higher 
titers of anti-BmpB IgG compared to those treated with the BmpB or 
BmpB-PLGA MPs. In addition, the anti-BmpB IgG titers of the mice 
treated with the BmpB-CKS9-WSC-PLGA MPs in serum 4 weeks after 
their first immunization were 4.9- and 4.2-fold higher compared to those 
treated with the BmpB and BmpB-PLGA MPs, respectively. 
The serum isotype levels of IgG1 and IgG2a were determined to 
investigate the type of immune response. While the production of the IgG2a 
isotype is associated with a Th1-type response, the IgG1 isotype 
isassociated with a Th2-type response. The ratios of IgG2a/IgG1 are used to 
indicate the Th1 or Th2 bias of the generated immune response (Romagnani, 
2000; Maassen et al., 2003). The anti-BmpB IgG1 and IgG2a antibody 
responses in serum after immunization are shown in Figure 11 D. The mice 
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treated with BmpB-WSC-PLGA showed higher titers of antibody responses 
compared to those treated with the BmpB or BmpB-PLGA MPs. In addition, 
the anti-BmpB IgG1 titers of mice treated with the 
BmpB-CKS9-WSC-PLGA MPs in serum 4 weeks after the first 
immunization were 6.1- and 8.3-fold higher compared to those treated with 
the BmpB and BmpB-PLGA MPs, respectively. Furthermore, the 
anti-BmpB IgG2a titers of the mice treated with BmpB-CKS9-WSC-PLGA 
MPs in serum 4 weeks after the first immunization were 11.8- and 6.6-fold 
higher compared to those treated with the BmpB and BmpB-PLGA MPs, 
respectively. Because the BmpB- CKS9-WSC-PLGA MPs displayed 
elevated IgG1 and IgG2a titers, these MPs appear to induce both Th1and 
Th2 immune responses in vivo.  
The results of this study demonstrated that the oral immunization of mice 
with BmpB-WSC-PLGA MPs elevated immune responses due to 
mucoadhesive property of the WSC (Illum et al., 2001; Amidi et al., 2010), 
that enhanced the retention of BmpB in intestine, maximizing the 
interactions with M cells. Interestingly, the oral immunization of mice with 
the BmpB-CKS9-WSC-PLGA MPs dramatically increased sIgA responses 
in the mucosal tissues as well as systemic IgG antibody responses due to the 
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enhanced M cell targeting and transcytosis ability of the WSC-PLGA MPs 
to PP regions. 
 
 
Figure 11.  BmpB-specific immune response after oral administration.  
Anti-BmpB IgA levels in feces (A) and intestine (B), anti-BmpB IgG levels in 
serum (C) and anti-BmpB IgG subclass antibody (IgG1 and IgG2a) (D) levels 








Our results indicate that porous PLGA MPs coated with M cell homing 
peptide-coupled chitosan is a promising approach for the oral delivery of 
BmpB vaccine with successful stimulation of specific IgG in serum and 
sIgA in feces and intestine. Moreover, BmpB-CKS9-WSC-PLGA MPs 
demonstrated to induce both Th1-and Th2-type responses based on elevated 
IgG1 and IgG2a titers. Based on our present study, we believe that this 
approach would be applicable for swine dysentery vaccine delivery to 












Chapter 2. Oral delivery of probiotic expressing M cell 
homing peptide conjugated BmpB vaccine encapsulated 
into alginate/chitosan/alginate microcapsules 
1. Introduction 
Antibiotics have long been used for treating and preventing animal 
diseases, and improving feed efficiency of live stocks (Allen et al., 2013). 
But, due to the development of resistant pathogens associated with human 
and animal diseases, a comprehensive ban on the use of all antibiotics for 
growth promotion has been implemented in developed countries (Stanton, 
2013). Therefore, alternatives to antibiotics are urgently needed in food- 
producing animals. But, it is not easy to find them due to complexity of the 
gastrointestinal (GI) ecosystem (Allen et al., 2013). 
As an alternative, probiotics have received great attention due to their 
wide use in fermented foods and dairy products. Probiotics are live 
microorganisms which when administered in adequate amounts confer a 
health benefit on the host by improving its intestinal microbial balance. 
Where antibiotics kill not only the bad bacteria that can cause infection but 
also destroy the good bacteria that help fight infection, probiotics, on the 
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other hand, re-populate the intestinal flora with healthy bacteria that can 
help kill the bad bacteria and fight infection.  
Most importantly, probiotics can induce antigen-specific and non-specific 
IgA antibody responses at mucosal surfaces to prevent invasion by 
pathogenic microorganisms (Perdigón et al., 2001; Wells and Mercenier, 
2008b). Similarly, oral administration of probiotics regulate the Th1/Th2 
balance (Torii et al., 2007). It is now well-documented that probiotics 
stimulate human or murine dendritic cells to produce increased levels of 
pro-inflammatory cytokines (IL-2, IL-12, TNF-α) (Chiba et al., 2010; Weiss 
et al., 2010). Such immune stimulating effects are the characteristics of 
adjuvants. Therefore, probiotic adjuvants when orally administered in 
conjugation with vaccine repeatedly enhance the immunogenicity of 
vaccines. Altogether, probiotics modulate both mucosal and systemic 
immune responses and function as adjuvants by promoting 
pro-inflammatory cytokine production. 
Due to these advantages and no side effects, the probiotics are “generally 
regarded as safe” (GRAS), and they can manage to survive passage through 
the acidic conditions of the stomach when administered orally. Besides, 
these probiotic strains can be manipulated to express targeting molecules 
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and adjuvants by recombinant DNA techniques (Wells and Mercenier, 
2008a). Several attempts have also been made to use combinations of 
probiotics with other additives (e.g., vaccines or adjuvants) with the goal of 
increasing the effect of the probiotics synergistically (Bomba et al., 2002; 
Musa et al., 2009). Therefore, a better understanding of the effects and 
mechanisms of action of the combinations will allow to design more 
rational potentiated probiotics (Allen et al., 2013). 
Mucosal delivery of vaccines have several advantages such as 
elimination of the risk of transmission of blood-borne diseases, easy 
administration by personnel with less medical training and elicitation of 
both mucosal and humoral immunity  (Cutting et al., 2009). However, oral 
vaccine delivery has to overcome problems associated with poor absorption 
and degradation of the vaccine within the digestive system. Besides, 
mucosal vaccine adjuvants in current use do not confer the required efficacy 
and safety for clinical application. Therefore, the combination of the 
intrinsic advantages of probiotics, not only as a live vaccine delivery 
vehicle but also an immune enhancer, with other nano- or micro carrier 




Recently, an M cell homing peptide, screened by phage display technique, 
have shown high affinity to M cells to target Peyer’s patch regions (Yoo et 
al., 2010). For illustration, oral immunization of M cell homing peptide 
coated poly(lactic-co-glycolic) acid (PLGA) microparticles harboring 
BmpB (Brachyspira membrane protein B), a model antigen for swine 
dysentery (SD), showed high immune responses in the mucosal tissues 
(Jiang et al., 2014). In this study, we developed a probiotic strain through 
recombinant DNA technology that expresses and produces BmpB antigen 
fused with M cell homing peptide. The probiotic was encapsulated into 
alginate/chitosan/alginate (ACA) microcapsules (MCs) and later delivered 
through oral route to evaluate the efficiency of vaccine delivery and 







2. Materials and methods 
1). Materials 
Sodium alginate (low viscosity), L-glutamine, glycerol, ribonucleosides, 
pepsin, bile salt (B8756), deoxyribonucleosides, bovine serum albumin 
(BSA), fluorescein isothiocyanate (FITC), 4′,6-diamidino-2-phenylindole 
dihydrochloride (DAPI), N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3- 
dimethylaminopropyl)-carbodiimide hydrochloride (EDC) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Recombinant mouse 
granulocyte macrophage colony stimulating factor (mGM-CSF) was 
purchased from Peprotech (Rocky Hill, NJ, USA). Chitosan (MW 150,000; 
degree of deacetylation = 91.8%) was kindly provided by Jakwang Co. Ltd. 
(Ansung, Korea). DifcoTM Lactobacilli MRS broth and Lactobacilli MRS 
agar were purchased from BD (Sparks, MD, USA). Fetal bovine serum 
(FBS), mouse TNF-α ELISA and mouse IL-6 ELISA were purchased from 
Thermo Scientific (Rockford, IL, USA). 3,3’,5,5’-tetramethyl benzidine 
(TMB), horseradish peroxidase (HRP)-conjugated goat anti-mouse IgA, 
IgG, IgG1 and IgG2a antibody were purchased from Santa Cruz 




2). Probiotic strains 
Lactobacillus plantarum 25-wild type (LP25-WT) was used as a model 
probiotic strain (Yun et al., 2009). The recombinant LP25 expressing BmpB 
or M cell homing peptide conjugated BmpB (M-BmpB) were constructed 
by our research group (Table 1). 
 
Table 1. Formulations used in this study. 
 
Cohort Formulation Description 
1 Control Saline (0.85%) 
2 ACA MCs Alginate-Chitosan-Alginate 
Microcapsules 
3 LP25-WT L. plantarum 25 wild type 
4 LP25-BmpB L. plantarum 25 expressing BmpB 
5 LP25-M-BmpB L. plantarum 25 expressing M cell 
homing peptide conjugated BmpB 




L. plantarum 25 expressing BmpB 
encapsulated into ACA MCs 
8 LP25-M-BmpB-ACA 
MCs 
L. plantarum 25 expressing 





3). Synthesis of FITC-labeled chitosan 
FITC-labeled chitosan (FITC-C) was prepared as follows. Chitosan 
solution (5% w/v in distilled water, 4 ml) was prepared, followed by the 
addition of FITC (2 mg/ml in DMSO, 1 ml). The reaction was carried out in 
dark at RT with stirring for 24 h. To remove unreacted FITC, the solutions 
were dialyzed against distilled water at 4°C. The dialyzed product was then 
freeze-dried. 
4). Synthesis of DAPI-labeled alginate 
DAPI-labeled alginate (DAPI-A) was prepared by conjugation of 
alginate with DAPI using NHS/EDC coupling agents. Briefly, alginate (100 
mg) was dissolved in 2 ml distilled water and activated with NHS (131 mg) 
and EDC (218 mg) at RT for 3 h. The resultant solution was added into the 
DAPI solution (0.26 mg was dissolved in 1 ml distilled water) and stirred in 
dark at RT for 24 h. The reaction product was dialyzed for 2 days against 
distilled water and then freeze-dried. 
5). Microencapsulation of probiotic strains 
Wild type or recombinant LP25 cultured in MRS broth was centrifuged at 
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2000×g at 4 °C for 10 min. The probiotic pellets were washed and 
suspended in 5 ml of normal saline. MCs were prepared by centrifugal 
extrusion method as previously described (Bajracharya et al., 2012; Jiang et 
al., 2013) with slight modification. Briefly, the mixture of sodium alginate 
with LP25 (or recombinant LP25) and 15% (v/v) glycerol was dropped into 
0.1M CaCl2 by passing through cannula-like syringe in the presence of N2 
gas pressure. Gelation of the alginate droplets by calcium ions immediately 
formed alginate MCs, the final concentration of sodium alginate being 1.5 % 
(w/v). Alginate MCs thus formed were allowed to harden by incubation 
with 0.1M CaCl2 solution for 30 min and they were washed with 0.85% 
saline to remove unreacted CaCl2. Then, the alginate MCs were coated with 
0.8% (w/v) chitosan solution for 30 min followed by two times washing by 
0.85% saline. Chitosan-coated alginate MCs were further coated with 0.1% 
(w/v) sodium alginate for 10 min followed by washing. They were stored at 
-70 °C for 6 h and lyophilized. ACA MCs without probiotics were prepared 
in the same way following the same protocol as described above. The 





Figure 1. Process of microcapsules preparation. 
 
6). Detection of coatings by confocal microscopy 
Alginate MCs were prepared by gelation of alginate droplets by calcium 
ions as described above. The alginate MCs were placed in 0.8% (w/v) 
FITC-C solution for 30 min followed by two times washing by 0.85% 
saline. Chitosan-coated alginate MCs were further coated with 0.1% (w/v) 
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DAPI-A solution for 10 min followed by washing. The MCs were examined 
on confocal laser scanning microscope (CLSM; Leica TCS SP8X Gated 
STED, Germany). 
7). Morphology observation and size measurement of MCs 
Prior to observation of the morphology of MCs, the MCs were coated 
with gold using coating chamber (CT 1500 HF, Oxford Instruments Oxford 
shire, UK). The coated MCs were observed through field-emission scanning 
electron microscope (FE-SEM) (Supra 55VP; Carl Zeiss, Oberkochen, 
Germany). The settings of SEM images are as follows: (Mag = 100 X; WD 
= 6.6 mm; EHT = 7.0 kV). The average size of the MCs was calculated 
using a hemocytometer (Tiefe Depth Profondeur 0.100 mm, Paul 
Marienfeld, Germany). 
8). Loading and releasing behavior of probiotics in MCs 
The encapsulation efficiency (EE) was expressed as the percentage of the 
probiotics amount found in the MCs to the total amount used to prepare the 
MCs. The loading content (LC) was expressed as the number of live 
bacteria (cfu: colony-forming units) found in the MCs, as described in a 
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previous report (Jiang et al., 2013). Briefly, ACA MCs are incubated in 
MRS broth at 37°C shaking with 100 rpm for a given interval of time. To 
test the release of probiotics from ACA MCs, an aliquot (10 µl) of the broth 
is dropped into the MRS agar plate and incubated at 37°C to count the 
colonies of the probiotics. 
Simulated gastric fluid (SGF) and simulated small intestinal fluid (SIF) 
were prepared by adjusting the pH of MRS broth medium to 2 and 7.2 
respectively (Kim et al., 2008). Survivability of free and encapsulated 
probiotics in SGF with or without pepsin (1000 units/ml) was calculated by 
cfu counting of probiotics after incubating at 37°C at 100 rpm against time. 
Similarly, survivability of free and encapsulated probiotics in SIF with final 
bile salt concentrations (1.2 % w/v) was checked by following the same 
method. Encapsulated probiotics were incubated in 10 ml of SIF at 37 °C 
with 100 rpm shaking. At a given time interval, 0.5 ml aliquot was collected 
and replaced by an equal volume of fresh medium. The release of probiotics 
was then assayed by counting cfu as described before (Lee et al., 2004). 
Freeze dried LP25-encapsulated ACA MCs were stored at 4°C and RT. 
Survivability of LP25-encapsulated ACA MCs was monitored as described 
above for 8 consecutive weeks. 
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9). Measurement of cytokine inductionfrommacrophagesor de
ndritic cells by probiotics 
The murine macrophages, RAW 264.7, were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) FBS. 
The murine dendritic cells, JAWSII, were maintained in α-minimum 
essential medium containing 20% (v/v) FBS, ribonucleosides and 
deoxyribonucleosides, 4 mM L-glutamine, 5 ng/ml mGM-CSF. Both cells 
were plated in 10 cm dish with the cell density of 1x107 cells per dish. To 
measure the amount of TNF-α and IL-6 cytokines secreted from RAW 
264.7 and JAWSII cells respectively, the cells were stimulated with the 
probiotics following the previously described method (Chon et al., 2010). 
The cells were incubated with free LP25 (1x108 cfu/dish), LP25-loaded 
ACA microcapsules (1x108 cfu/capsule/dish), unloaded ACA microcapsules 
(1 capsule/dish). 
10). Oral immunization 
Female BALB/c mice of 6 weeks of age were obtained from Samtako, 
Co. Ltd. (Osan, Korea). Animals were kept under standard pathogen-free 
conditions and supplied with free access to water and food during the 
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experiments. The animals were maintained and used in accordance with the 
guidelines for the care and use of laboratory animals (Seoul National 
University). The mice were divided into 8 cohorts (5 mice per cohorts). 
Peroral immunization with mice were performed with a dose of probiotics 
containing 109 cfu or freeze-dried MCs (10 MCs per mouse containing 109 
cfu) resuspended in the appropriate volume of 0.85% saline (200 ul) 
administered by intra-gastric inoculation using a disposable feeding needle. 
All cohorts received a total of six doses of the probiotics (or control) on 
days 0, 1, 7, 8, 14 and 15 (Figure 2). 
 
 
Figure 2. Scheme of oral immunization. 
 
To investigate immune responses, tail vein blood and feces samples were 
taken at 0, 7, 14, 21 and 28 days prior to immunization where appropriate. 
The blood samples were centrifuged for10 min at 3,000×g, and the 
collected serum was stored at -70°C until analysis for IgG, IgG1 and IgG2a 
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levels. To analyze the IgA level from fecal samples, five fecal pellets of 
each mouse selected randomly were prepared according to the method 
described previously (Jiang et al., 2014). Briefly, pellets in 1 ml phosphate 
buffered saline (PBS) were incubated for 15 min on ice and followed by 
mashing it with a blunt needle. Samples were centrifuged and IgA was 
analyzed as previously described (Enioutina et al., 1999). Finally, small 
intestines (3 cm) with Peyer’s patches of the mice were collected after 
sacrifice. The intestines were homogenized in 500 µl of ice-cold PBS. After 
removing tissues by centrifugation (10,000×g, 10 min and 4 °C), the 
supernatants were collected and stored at -70 °C until analysis for IgA level. 
11). Evaluation of antibody induction 
Induction of BmpB-specific antibodies was assayed using enzyme-linked 
immunosorbent assays (ELISA) as described before (Jiang et al., 2014). 
ELISA plates coated with BmpB (25 µg/ml), prepared in coating buffer 
(0.05 M carbonate-bicarbonate buffer, pH 9.6), were incubated at 4°C 
overnight. The plates were then washed with washing solution (PBS 
containing 0.05% (v/v) Tween 20) and blocked with blocking solution (PBS 
containing 1% (w/v) BSA). Serially diluted samples (100 µl/well) in 
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blocking solution were then added, and the mixtures were incubated for 2 h. 
After washing for three times, each sample was treated with 
HRP-conjugated goat anti-mouse IgG, IgG1 and IgG2a antibody (1:5000) 
or goat anti-mouse IgA antibody (1:2000). After 1 h incubation and 
subsequent washing, the samples were treated with TMB substrate buffer 
and the reaction was stopped after 15 min with 50 µl of 2 M H2SO4. The 
optical densities (OD) of the samples were measured at 450 nm by an 
Infinite 200 PRO multimode reader (Tecan, Switzerland). 
12). Statistical analysis 
All results are expressed as mean ± SD. Differences between means were 
tested for statistical significance using a one-way analysis of variance 
(ANOVA) and post hoc least significance tests. Statistical significance is 






3. Results and Discussion 
1). Characterization of probiotic-loaded ACA MCs 
Capsules of non-labeled alginate core treated with FITC-C and DAPI-A 
were prepared and examined through CLSM as shown in Figure 3. The 
images indicated that the surface of the MCs is homogeneously coated with 
chitosan and alginate due to the interactions between oppositely charged 
polymers (Bartkowiak and Hunkeler, 2000; Cook et al., 2011). 
Figure 4 shows SEM images of ACA MCs loaded with probiotics. The 
MCs were generally spherical with wrinkled surface that is probably due to 
the loss of water content during the freeze-drying process (Kwok et al., 
1991). It was observed that there was only a slight difference in size 
(around 1.11 mm) and shape of MCs among ACA MCs and 
probiotic-loaded ACA MCs, indicating that loading of probiotics or 
probiotics expressing vaccine did not affect size and shape of ACA MCs. 
Consistently, the size of the MCs does not affect the morphological 
characteristic of the capsule membrane. 
Loading characteristics of probiotics into ACA MCs are shown in table 2. 
The results indicated that sizes of ACA MCs increased from around 1 mm 
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to 2 mm with the increase of loading content of probiotics into MCs. 
However, encapsulation efficiency of MCs did not change with the loading 
content. 
 
Table 2. Characterization of prepared MCs. 
 





Unloaded 0.71±0.10 - - 
LP25-WT 
1.06±0.08 1.11±0.03×107 98.30 ± 2.31 
1.11±0.22 2.08±0.09×108 98.56 ± 1.33 
2.09±0.26 1.81±0.05×109 97.36 ± 2.37 
LP25-BmpB 
1.12±0.27 1.32±0.10×107 97.20 ± 3.13 
1.19±0.14 1.65±0.08×108 98.10 ± 2.23 
2.20±0.30 1.81±0.11×109 97.56 ± 1.33 
LP25-M-BmpB 
1.18±0.13 0.96±0.04×107 97.42 ± 3.75 
1.09±0.27 1.87±0.09×108 97.82 ± 2.07 





Figure 3. Confocal microscopy image showing layer of chitosan (green) and 








Figure 4. Morphologies of ACA MCs (a), LP25-WT-ACA MCs (b), LP25- 
BmpB-ACA MCs (c) and LP25-M-BmpB-ACA MCs (d) by field emission sca
nning electron microscope. Scale Bars: 500 µm. 
 
2). Survivability of LP25 encapsulated into ACA MCs 
Encapsulation of probiotics significantly improves survival, compared to 
free cells, while drying improves stability of the encapsulated culture during 
prolonged storage (Solanki et al., 2013). Therefore, we performed all the 
experiments using freeze-dried MCs. The freeze-dried formulations are 
easy to handle and less susceptible to breakage. Drying also create 
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mechanically stable MCs which are desirable property for oral delivery. 
Therefore, LP25 encapsulated into ACA MCs were freeze-dried to evaluate 
the storage stability at different temperature and conditions. Figure 5a 
shows the survivability of probiotics against time in SGF condition (pH 2.0) 
at 37 °C. The survivability of probiotics, both wild type and recombinants, 
drastically decreased within 2 h and the survivability was almost zero 
within 60 min in the presence of pepsin in SGF condition at 37 °C (Figure 
5b). The expression of recombinant proteins, BmpB or M-BmpB, did not 
affect the survivability of the probiotics. On the other hand, the 
survivability of probiotics increased after encapsulation into ACA MCs 
(Figure 5c) due to the protection by the capsules at the harsh gastric 
condition despite the presence of pepsin (Figure 5d). 
Figure 5e shows survivability of LP25 against time in SIF (pH 7.2) at 
37 °C in the presence of bile salt. The survivability of the LP25 drastically 
decreased within 24 h and decreased with an increase of bile salt. However, 
the survivability of the LP25 encapsulated into ACA MCs (Figure 5f) 





Figure 5. Viability of free and encapsulated probiotics during exposure to SGF 
(pH 2.0) and SIF (pH 7.2). SGF without pepsin (a, c); SGF with pepsin (b, d); 
SIF with bile salts (e, f). Viability represents the percentage of cells surviving 






The final challenge related to the development of probiotics 
encapsulation into ACA MCs is represented by their stability during storage. 
Figure 6a shows the survivability of probiotics against storage time at RT 
and 4°C. The results indicated that the viability of free probiotics after 5 
weeks of storage at 25°C was null whereas encapsulated probiotics had 
much better stability at 25°C with 30% survivability until 8 weeks. On the 
other hand, the survivability of free probiotics at 4°C was around 25% at 8 
weeks whereas the survivability of probiotics encapsulated into ACA MCs 
at 4°C was around 60% at 8 weeks (Figure 6b). Taken together, the viability 
of encapsulated probiotics stored at 4°C was 50 % higher than the storage at 
25°C. 
3). In vitro release of probiotics encapsulated into ACA MCs 
Beyond the protection of probiotics by MCs, they need to withstand the 
low pH of the stomach during oral delivery, and disintegrate in the gut to 
release the probiotics. Hence, in vitro release of probiotics encapsulated 
into ACA MCs was performed at pH 7.2 at 37 °C. The results demonstrated 
that around 75% of probiotics released within 1 h from the ACA MCs 
before freeze drying (Figure 7a), suggesting the rapid release due to 
hydrophilic property of the ACA MCs in SIF. Almost 100% of probiotics 
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released within 12 h from the ACA MCs before freeze drying. After freeze 
drying, only 50% of probiotics released during the initial 1 h from the ACA 
MCs (Figure 7b). Although the initial release of the probiotics retarded after 
freeze drying of MCs, the release reached almost 100% within 12 h similar 
to ACA MCs before freeze drying. It is likely that freeze-dried MCs takes 
longer time for rehydration to release the probiotics. 
 
 
Figure 6. Viability of free and encapsulated probiotics during 8 weeks of 
storage at RT (a and c) and 4°C (b and d). Viability represents the percentage of 





Figure 7. Release of probiotics from ACA MCs in vitro against at pH 7.2 at 






4). Measurement of cytokine induction 
A vaccine can work most efficiently, if it is able to elicit both humoral 
and cellular immune responses; however, conventional vaccines often 
induce antibody responses with only limited cellular immunity (Chadwick 
et al., 2010). M cells serve as a specific gate for antigens and have the 
ability to transcytose the antigenic material into the M cell pocket located 
below follicle-associated epithelium of the Peyer's patch facilitating 
delivery to antigen-presenting cells including dendritic cells and 
macrophages (Russell-Jones, 2000). The ability of probiotic bacteria to 
modulate immune responses are well recognized (Fujiwara et al., 2004; 
Elmadfa et al., 2010). It is also well-documented that IL-6 is a B cell 
differentiation factor that induces B cell proliferation leading to humoral 
immune responses whereas TNF-α induces T cell proliferation that 
increases the capacity of macrophages to phagocytose and kill the 
pathogens through cellular immune responses (Koppolu and Zaharoff, 
2013). In addition, induction of Th1 mediated immune response (associated 
with IgG2a antibody response) supports cellular immunity (van Ginkel et 
al., 2000). These responses help identify correlates of protective cellular 
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immunity by oral immunization with probiotics. Therefore, induction of 
cytokines (particularly, IL-6 and TNF-α) from macrophage cell line RAW 
264.7 after treating with the probiotics was assayed by ELISA. From 
ELISA test, it was observed that the free probiotics induced significantly 
higher level of cytokines production, both IL-6 (Figure 8a) and TNF-α 
(Figure 8b), from RAW 264.7 cells than probiotics-loaded ACA MCs. The 
consequence is due to controlled release of probiotics from probiotic-loaded 
ACA MCs. Importantly, the observed cytokine production from 
probiotic-loaded ACA MCs was due to the released probiotics, not due to 
microcapsule itself as it induced only negligible amount of cytokine 
production. Similar results of cytokine production were obtained in the 






Figure 8. Secretion of TNF-а and IL-6 from RAW 264.7 (a, b) and JAWSII (c, 
d) stimulated with free and encapsulated probiotics (means±SD, n=3, **p < 
0.01). 
 
5). In vivo immune responses 
Specific antibodies that inhibit pathogen adherence to receptors on the 
intestinal cells are important for the protection against animal diarrhea 
(Winner et al., 1991; Michetti et al., 1992; Zhang et al., 2002; Haesebrouck 
et al., 2004). For protection against diseases in young piglets, vaccines that 
stimulate mucosal immunity are necessary (Remer et al., 2009). Therefore, 
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the main goal of this work was to investigate the protective effect by ACA 
encapsulation for gastro-intestinal delivery of model vaccine (BmpB or 
M-BmpB) producing probiotics against harsh digestive conditions in the 
gastro-intestinal tract. In order to do this, we measured the antibody 
induction levels from mucosal and systemic immune responses compared to 
controls as showed in Figure 9.  
When the local sIgA levels present in the feces and intestinal were 
checked, the mice treated with LP25-BmpB-ACA MCs showed the highest 
level of anti-BmpB IgA in feces among LP25-WT, LP25-BmpB, 
LP25-M-BmpB and LP25-WT-ACA MCs as shown in Figure 10a. 
Particularly, the mice treated with LP25-M-BmpB-ACA MCs at 4 weeks 
after the first immunization showed 3.3- and 2.9-fold higher level of 
anti-BmpB IgA production than the mice treated with LP25-BmpB and 
LP25-M-BmpB, respectively, indicating that BmpB expressed in LP25 act 
as apotent antigen. The consequence was particularly due the protection of 
LP25 at gastric condition by ACA MCs while M cell homing peptide fused 
with BmpB enhanced high accessibility of vaccine molecules to gut 
associated lymphoid tissues (GALT) and Peyer’s patch regions through M 
cells. Due to their transcytotic capability, intestinal M cells represent an 
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efficient potential route for vaccine delivery (Sansonetti and Phalipon, 1999; 
Ann Clark et al., 2001).  
 
 
Figure 9. Schematic representation of induction of both mucosal and systemic 
immune responses at the mucosal-associated lymphoid tissue in the intestine by 
oral delivery of LP25-M-BmpB-ACA MCs. 
 
The anti-BmpB IgA antibody production in the intestine at 4 weeks after 
the first immunization is shown in Figure 10b. The mice treated with the 
LP25-M-BmpB-ACA MCs showed higher level of anti-BmpB IgA 
production showing similar tendency of IgA production in feces. 
Particularly, the level of IgA production in the mice treated with the 
LP25-M-BmpB-ACA MCs was 5.4- and 2.1-fold higher than those treated 
with the LP25-BmpB and LP25-M-BmpB, respectively. Although humoral 
immunity at the mucosal area is mainly mediated by IgA antibody as the 
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predominant immunoglobulin, locally produced IgG and serum-derived IgG 
also contribute to immune defense (Azizi et al., 2010). Therefore, the 
anti-BmpB IgG antibody responses in serum after immunization are also 
evaluated. As shown in Figure 10c, the mice treated with 
LP25-M-BmpB-ACA MCs displayed higher level of anti-BmpB IgG than 
those treated with the LP25-WT and LP25-BmpB. However, there was no 
prominent difference of anti-BmpB IgG between LP25-BmpB and 
LP25-BmpB-ACA MCs at 3 weeks. In particular, the anti-BmpB IgG level 
of the mice treated with LP25-M-BmpB-ACA MCs in serum at 4 weeks 
after the first immunization were 2- and 1.7-fold higher than those treated 
with the LP25-BmpB and LP25-M-BmpB, respectively. 
The serum isotype levels of IgG1 and IgG2a are assayed to check the 
type of immune response as the production of the IgG2a isotype is related 
with a Th1-type response whereas the IgG1 isotype is related with a 
Th2-type response. Generally, the ratio of IgG2a/IgG1 indicate the Th1 or 
Th2-type bias of the generated immune response (Romagnani, 2000; 
Maassen et al., 2003). The anti-BmpB IgG1 and IgG2a antibody production 
in serum at 4 weeks after the first immunization is shown in Figure 10d. It 
was found that the mice treated with LP25-M-BmpB displayed higher level 
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of antibody responses than those treated with the LP25-WT and 
LP25-BmpB although there is not much difference of anti-BmpB IgG1 and 
IgG2a between LP25-BmpB and LP25-BmpB-ACA MCs. Particularly, the 
level of anti-BmpB IgG1 in mice treated with the LP25-M-BmpB-ACA 
MCs in serum at 4 weeks after the first immunization were 2- and 1.4-fold 
higher than those treated with LP25-BmpB and LP25-M-BmpB, 
respectively, suggesting that the LP25-M-BmpB-ACA MCs appears to 
induce both Th1 and Th2 immune responses in vivo due to the simultaneous 
elevation of IgG1 and IgG2a levels. The results of this research indicated 
that oral immunization of mice with LP25-BmpB-ACA MCs elevated 
immune responses due to expression and production of recombinant BmpB 
in LP25, protection of antigen by the ACA MCs and interactions of M cell 
homing peptide fused to antigen with M cells in the gut. Moreover, the oral 
immunization of mice with LP25-M-BmpB-ACA MCs drastically increased 






Figure 10. BmpB-specific immune response after oral administration. 
Anti-BmpB IgA levels in feces (a) and intestine (b), anti-BmpB IgG levels in 
serum (c and anti-BmpB IgG subclass antibody (IgG1 and IgG2a) (d) levels 
were measured using ELISA. (means±SD, n=5 mice, **p < 0.01). 
4. Conclusions 
In present study, the use of ACA MCs to deliver probiotic expressing M 
cell homing peptide fused BmpB antigen showed successful stimulation of 
specific IgG in serum and IgA in feces and intestine of mice. Future 
efficacy studies are needed to evaluate whether and/or how ACA MCs 





A successful drug delivery application depends on the effectiveness and 
suitability of the delivery system. The participation of a variety of natural as 
well as synthetic polymers and their applications in various drug delivery 
systems is a revolution. The versatility and diversity of polymer chemistry 
greatly offer to design suitable polymeric carriers with desired properties to 
establish effective drug delivery systems. Oral administration is the most 
attractive route for drug delivery compared to other systems where 
polymeric carriers have effective applications to limit the demerits 
associated with oral administration of drug.  
In Chapter I, we have developed an efficient oral vaccine carrier that 
constitutes PLGA MPs coated with M cell targeting peptide to overcome 
the some barrier, such as degradation of the vaccine in the gastrointestinal 
(GI) tract due to the low pH and enzymes in the stomach, the impermeable 
GI epithelium as a physical barrier and inefficient targeting to the action site, 
resulting in a low bioavailability. In this study, BmpB as a model vaccine 
against swine dysentery was loaded into porous PLGA MPs. The PLGA 
MPs was further coated with the water-soluble chitosan (WSC) conjugated 
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with M cell homing peptide (CKS9) to prepare BmpB-CKS9-WSC-PLGA 
MPs. Oral immunization of BmpB vaccine with CKS9-WSC-PLGA MPs in 
mice showed elevated sIgA responses in the mucosal tissues and systemic 
IgG antibody responses, providing a complete immune response. 
Specifically, the immunization with these MPs demonstrated to induce both 
Th1- and Th2-type responses based on elevated IgG1 and IgG2a titers. The 
elevated immune responses were attributed to the enhanced M cell targeting 
and transcytosis ability of CKS9-WSC-PLGA MPs to Peyer’s patch regions. 
The high binding affinity of CKS9-WSC-PLGA MPs with the M cells to 
enter into the Peyer's patch regions of mouse small intestine was 
investigated by closed ileal loop assay and it was further confirmed by 
confocal laser scanning microscopy. These results suggest that the M cell 
targeting approach used in this study is a promising tool for targeted oral 
vaccine delivery. 
In Chapter II, we have developed an efficient oral vaccine carrier that the 
encapsulation of vaccine-expressed probiotics into ACA MCs for efficient 
oral vaccine delivery, to overcome the some barrier, such as the low 
survival of probiotics in the gastrointestinal tract limits and inefficient 
targeting to the action site, resulting in a low bioavailability. Here, 
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recombinant Lactobacillus plantarum 25 (LP25) expressing M cell homing 
peptide fused BmpB protein was used as a model strain. The viability of 
LP25 in ACA MCs was more than 65% in simulated gastric fluid (SGF, pH 
2.0) and 75% in simulated small intestinal fluid (SIF, pH 7.2) up to 2 h. 
Encapsulated LP25 were completely released from ACA MCs in SIF within 
12 h. When stored at room temperature or 4°C, the viability of LP25 in 
ACA MCs was higher than free LP25. Interestingly, the viability of LP25 in 
ACA MCs at 4°C for 5 weeks was above 58%, whereas viability of free 
LP25 stored at room temperature up to 5 weeks was zero. After 4 weeks 
from the first immunization, LP25-M-BmpB-loaded ACA MCs induced a 
stronger BmpB-specific IgG and IgA production in mice. These findings 
suggest that encapsulation of LP25 by ACA MCs is a promising delivery 
system for oral administration of vaccine-expressed probiotic. 
The currently designed and evaluated polymeric carriers provided 
effective delivery systems in mice for oral administration of 
afore-mentioned vaccines and probiotics. Additional investigations should 
be performed in pigs for future advancements of these novel polymeric 
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Oral delivery of probiotics in poultry using pH-sensitive 
tablets 
1. Introduction 
Recently, many developed countries have banned on the use of 
antibiotics for treating and preventing animal diseases, and 
growth-promoting of live stocks (Allen et al., 2013) due to the appearance 
of resistant pathogens related with human and animal diseases (Stanton, 
2013). Although alternatives to antibiotics in live stocks are urgently 
required, it is very hard to find them due to the complexity of the 
gastrointestinal (GI) ecosystem (Allen et al., 2013). 
As a substitute, probiotics may replace the antibiotics as they can inhibit 
colonization of pathogens on the intestinal receptor. Usually, probiotics 
confer a health benefit on the host by improving their intestinal microbial 
balance that can help kill the bad bacteria and fight infection. As a 
consequence, probiotics are generally regarded as safe, and therefore, they 
are extensively used in food products. Moreover, they can manage to 
survive under the acidic conditions of stomach when administered orally 
although the rate of survival is strain-dependent (Wells and Mercenier, 
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2008). Among probiotics, Pediococcusacidilactia (PA) has been reported to 
confer antimicrobial activity against Salmonella gallinarum, a major 
pathogen of poultry (Lee et al., 2007). 
Oral delivery of probiotics, as one of therapeutics in animals, is highly 
promising due to easy handling, reduced time, low cost and reduced labor. 
However, oral delivery of probiotics has to overcome several problems 
associated with the instability of the probiotics at acidic pH condition of 
stomach and abundant enzymes in intestine, and poor absorption of 
probiotics in intestine (Klayraung et al., 2009). Therefore, pH-sensitive 
polymers in the form of tablets using hydroxypropyl methylcellulose 
phthalate (HPMCP) (Klayraung et al., 2009), hydroxypropyl 
methylcellulose acetate succinate (HPMCAS) (Stadler and Viernstein, 
2003), cellulose acetate phthalate (CAP) (Silva et al., 2013) and 
carboxymethyl high amylase starch (CM-HAS) (Calinescu et al., 2005) 
have been used to deliver probiotics. Due to pH sensitive property of the 
polymers, the probiotics in the pH-sensitive tablets can be protected from 
gastric pH and harsh conditions found in the duodenum (Wang and Zhang, 
2012). However, pH-sensitive polymers were almost used to deliver the 
probiotics for human health benefit, not for animals. 
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In this study, we used pH-sensitive tablets for oral delivery of probiotics 
in poultry. The probiotic-loaded tablets have several advantages such as 
simple and convenient production, resistance to environment, easy control 
of dosage and high patient compliance. 
2. Materials and methods 
1) Materials 
Genome shuffled (GS1) PA was constructed (Song A, 2012) to improve 
antimicrobial activity of wild-type PA. HPMCP 55 was kindly provided by 
Shin-Etsu Chemicals Ltd. (Tokyo, Japan). DifcoTM lactobacilli MRS broth 
and lactobacilli MRS agar were purchased from BD (Sparks, MD, USA). 
Novobiocin, nystatin, vancomycin and other chemicals were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). 
2) Preparation of tablets 
Tablets were prepared by a direct compression using a single tablet press 
at room temperature. An exactly weighed powder mixture (25 mg) of GS1 
and HPMCP (weight ratio of GS1 to HPMCP= 1:1) was filled into a die of 
4 mm diameter and the tablets were formed under a determined pressure 
ranging from 3 to 10 kilopascal (KP) with a plane surface. 
3) Viability test in tablets 
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3-1) Viability assay of GS1 inside the tablet 
Each tablet was broken and dispersed in 1 ml of phosphate buffer 
solution (PBS, pH 7.2). The GS1 suspension was then spread onto the 
pre-dried MRS agar plates. Then, the plates were incubated at 37 ℃ for 
24-36 h. Colonies of GS1 were counted and converted to log cfu (colony 
forming units). The viability of probiotic cells was calculated by the 
following equation. 
Viability (%) = cfu after exposure to the test medium / cfu before equation 
to the test medium × 100 
3-2) Viability assay of GS1-loaded tablets in fluid media 
GS1-loaded tablets were transferred into 5 ml of simulated gastric fluid 
(SGF) (pH 2.0) or PBS (pH 7.2). After the end of the incubation period in 
the incubator (100 rpm at 37 ℃), the viable cells in the medium and 
non-disintegrated tested tablets were determined by the same method 
described above. 
4) Disintegration time of GS1-loaded tablets in PBS against 
compression force 
The test tablets prepared by different compression force were transferred 
into 5 ml of PBS (pH 7.2) and complete disintegration time of GS1-loaded 
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tablets was measured. 
5) Stability of GS1-loaded tablets 
For stability test during storage of the tablets, the GS1-loaded tablets 
were kept in tight light resistant containers at 4 ºC and room temperature up 
to 6 months. The stability of GS1 in terms of cell viability in the tablet was 
monitored as described above for 6 consecutive months. 
6) Oral administration in chicken 
Eleven day-old broiler chickens (Ross 308, mixed sex) were used for oral 
administration. The chickens were provided with free access to water and 
feeds during experiments. The chickens were used in accordance with the 
guide lines for the care and use of laboratory animals (Seoul National 
University). The chickens were divided into 3 cohorts (6 chickens per 
cohort). Per-oral administration in chickens were performed with a dose of 
probiotics containing 2×108 cfu suspended in the appropriate volume of 
pediococci selective medium (Leuschner et al., 2003) of 1 ml administered 
by intragastrical inoculation using a feeding needle or one tablet containing 
2×108 cfu. Only PBS was used as a control. All cohorts received a total of 5 
doses of the probiotics (or control) on hours 0, 4, 24, 28, and 48 (Figure 1). 
To investigate viable cells, the contents of the muscular stomach, small 
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intestines and cecum of the chicken were immediately collected after 
sacrifice. The contents were homogenized inappropriate volume of ice-cold 
PBS. The viable cells in the medium were determined by the same method 
described above. 
 
Figure 1. Scheme of oral administration in chicken. 
3. Results 
1) Effects of compression force and tablet properties on cell 
viability 
The effect of compression force during tabletting on viability of GS1 was 
investigated. It was found that viability of GS1 decreased slightly with an 
increase of compression force during tabletting as shown in Figure 2. The 
change in the morphology of tablet (compression force: 10 KP) was 
investigated by immersing the tablet in SGF (Figure 3). It was observed that 
the tablets showed no disintegration within 2 h in the gastric mimicking 
acidic medium. The viability of GS1 inside the non-disintegrated tablets 
after SGF immersion was then determined. The results showed that the 
viability of GS1 in the tablets decreased with the increase of immersion 
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time and increased with the increase of compression force as shown Figure 
4. 
Effect of compression force on disintegration time of GS1-loaded tablets 
in PBS (pH 6.8) was also investigated. As shown in Figure 5, disintegration 
time of the GS1-loaded tablets was increased with the increase of 
compression force. While the GS1-loaded tablets prepared with the highest 
compression force of 10 KP was hardly disintegrated within 1 h, those 
prepared from the compression force of 3 KP was disintegrated within 30 
min.  
 





Figure 3. Shape change of tablet incubated in SGF against time. 
2) Release of GS1 from GS1-loaded tablets in SGF and SIF 
Release test was done by immersing the GS1-loaded tablets for 1.5-2 h in 
SIF and the released probiotics were calculated. As shown in Figure 6, 
initially, after 1 h in SGF, no viable released probiotics from the 
GS1-loaded tablets were found in the gastric medium. The GS1-loaded 
tablets partially liberated probiotics during the first 30 min in SIF. The 
higher compression force during tabletting provided delayed liberation of 
the probiotics from GS1-loaded tablets. Figure 7 shows cell viability of the 
GS1 in the GS1-loaded tablets after immersing in fluid media of SGF and 
SIF. The results indicated that cell viability inside the GS1-loaded tablets in 
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SGF was slowly decreased with time and the cell viability in SIF was 
slightly changed after 7 h, indicating that the HPMCP 55 does not affect 
cell viability of the released probiotics from the GS1-loaded tablets in SIF. 
 
Figure 4. Survivability of GS1 in tablet at SGF (pH 2.0) without pepsin (a) 








Figure 6. Release of live bacteria from tablets during sequential exposure to 




Figure 7. Survivability of GS1 in tablet at SIF (pH 6.8) (means±SD, n=3, **p 
< 0.01). 
3) Stability of the GS1-loaded tablets 
Stability of probiotics in terms of cell viability is one of the major 
indexes which indicates the possibility of poultry excipients and dosage 
forms to protect the probiotics with long shelf life. Two different 
temperatures (4 ℃ and room temperature) were selected to evaluate the 
stability of the GS1-loaded tablets because the selected temperatures 
represent the common cool storage as in a household refrigerator and 
ambient room temperature, respectively. Figure 8 shows cell viability inside 
GS1-loaded tablets after storage at 4 ℃ and room temperature. The results 
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indicated that storage at room temperature caused more significant 
decreases in cell viability than storage at 4 ℃. After 6 months of storage at 
4 ℃, the loss of cell viability in the GS1-loaded tablets obtained at 
compression force of 10 KP was observed to be less than 1 log unit, 
indicating that storage temperature affects the cell stability. 
 
Figure 8. Viability of tablets during 6 months of storage at 4°C (a) and RT (b). 
118 
 
4) Oral administration in chicken 
Since the probiotics were orally given to chicken as either tablet or 
solution form, the viability of probiotics in 6 digestive areas such as 
muscular stomach (MS), up portion of small intestine (UI), middle portion 
of small intestine (MI), down portion of small intestine (DI) and cecum (CE) 
at 3 and 6 h after oral administration were investigated. As shown in Figure 
9 (a), more viable cells were observed by oral administration of the tablets 
than solution inseveral digestive areas of chicken at 3 h after oral 
administration, suggesting that the tablets could protect probiotics in the 
digestive areas of chicken. Especially, the survivability of probiotics was 
1.3, 1.3, and 1.25 folds higher in MS, MI and DI respectively, by delivering 
with tablets, than solution. After 6 h of administration, the survivability of 
probiotics was also higher by using the tablets than solution in several 
digestive areas except MS of chicken. Especially, the survivability of 







The probiotic products available in the market nowadays are mostly in 
the form of liquid or semisolid formulations which show low cell viability 
after oral administration, mainly because the bacteria do not survive the 
harsh conditions in the stomach. The development of suitable dry dosage 
forms enable higher bacterial survival and consequently is the main aim of 
the present study. The formulation of probiotics into tablets is an emerging 
method to reduce cell death during GI passage, as well as an opportunity to 
control release of these cells across the intestinal tract as a safe and 
effective oral delivery for feed supplement applications. In this study, the 
effects on bacterial survival during tabletting were investigated. The results 
suggested that the used compression force during tabletting does not affect 
the viability of GS1 which is consistent with the previous result (Calinescu 
et al., 2005). The viability of GS1-loaded tablets immersed in SGF after 2 h 
indicated that increasing the compression force to 10 KP improved the 
tablet efficacy in protecting bacterial cells against acidic challenge. 
Especially, the survivability of GS1 in GS1-loaded tablets obtained from 
compression force of 10 KP without pepsin and with pepsin after 2 h was 
80% and 75%, respectively, suggesting that the compression force is 
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considered to be one of the important tablet properties to protect the cells 
inside the tablet from the contact fluid. The disintegration time of the 
GS1-loaded tablets indicated that pH-sensitive HPMCP 55 as a tablet 
excipient with sufficient compression force allowed the preparation of 
GS1-loaded tablets with suitable properties in terms of long disintegration 
time and high probiotic cell viability. 
The release of the probiotics is closely related to tablet swelling because 
the HPMCP 55 is insoluble in SGF and soluble in SIF due to the 
pH-sensitive property. Also, the swelling degree of the HPMCP 55 
increased at pH 6.8 than at pH 2.0. The release behavior of GS1 release 
from GS1-loaded tablets suggested that the release of probiotics from the 
GS1-loaded tablets can be controlled by the compression force. 
The main goal of this work was to evaluate the use of pH-sensitive 
tablets for efficient oral delivery of probiotics in poultry. Generally, it has 
been reported that the transient time of the ingested food from the stomach 
to the intestinal tract for the chicken is about 3 h (Vanbelle M, 1999). 
Therefore, the tablets should ideally protect probiotics until this time and 
then should release viable probiotics in the intestinal tract. Here HPMCP 55 
tablets prepared with compression force of 10 KP were disintegrated within 
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2 h in the SIF. Viable cells in GI at 3 and 6 h after oral administration of 
GS1-loaded tablets in chicken were investigated. It was observed that the 
survivability of probiotics was higher inseveral digestive areas of chicken at 
3 h after oral administration of tablet than solution, suggesting that the 
tablets can protect and control release of the probiotics in the digestive 
areas of chicken. 
 
4. Conclusions 
This research showed that the extent of cell survival depended on 
the compression force of the tablets using pH-sensitive HPMCP 55 as a 
matrix forming material and the probiotics formulated in the tablets were 
protected at the harsh conditions of stomach in vitro and in digestive areas 
of chicken. Almost probiotics were preserved as viable cells when the 
tablets were stored at 4°C for 6 months. These results suggest the possibility 







Figure 9. Viable cells of digestive system. UI: up portion of small intestine, 
MS: muscular stomach, MI: middle portion of small intestine, CE: cecum, DI: 
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Summary in Korean 
경구를 통한 백신 전달방식은 기타 경로 비해 환자에게 거부감이 
없고 스스로 쉽게 조작방법에 따라 투여할 수 있을 뿐 더러 생산적인 
측면에서 가격이 저렴하며 또 주사에 따른 고통과 감염의 위험성이 적다. 
또한 경구를 통한 백신은 체순환면역반응과 점막면역반응을 동시에 
유도할 수 있어서 우수한 백신전달 방법으로 각광을 받고 있다. 그러나 
경구백신은 위산과 소화 장관의 효소에 의한 방해로 인해 백신 혹은 
생균제를 포함한 경구전달 약물들의 생물학적 이용도가 떨어지는 
제한점이 있다. 이러한 문제점들은 조절방출(control release)할 수 있는 
폴리머 기반의 전달체를 이용하여 위산과 소화 장관의 효소로부터 
전달약물을 보호함으로써 극복할 수 있다.  
첫 번째 연구는 poly(lactic-co-glycolic acid)(PLGA) 마이크로 
입자에 M 세포 표적형 펩타이드를 연결시킨 경구 백신 전달체의 
개발이다. 소장 점막면역 유도에 있어 핵심이 되는 M 세포는 백신을 
점막 면역 조직에 효과적으로 전달할 수 있는 한 개의 관문 역할을 한다. 
이 연구에서는 Brachyspira hyodysenteriae (BmpB)의 외각 단백질을 
돼지 설사병에 대한 모델 백신으로 다공성의 PLGA 마이크로 입자 
(MPs)에 담지시켰다. 또한, BmpB-CKS9-WSC-PLGA MPs 를 구성하기 
위해 PLGA MPs 에 수용성의 키토산 (WSC)을 코팅하고 M 세포 표적형 
펩타이드 (CKS9)를 접합시킴으로써 M 세포를 표적할 수 있는 능력을 
부여하였다. BmpB 백신을 담지한 CKS9-WSC-PGLA MPs 은 경구를 
통한 면역을 통해 쥐의 점막 조직에서 IgA 의 분비 반응, 체순환 IgG 
항체의 반응을 상승시킴으로써 효과적인 면역 반응을 보였다. 특히, 
MPs 을 이용한 면역은 Th1 타입과 Th2 타입의 면역반응, 즉 그 지표인 
IgG2a 와 IgG1 을 통해 모두 증가하는 것을 확인하였다. 이러한 
면역반응은 CKS9-WSC-PLGA MPs 의 M 세포 표적능력으로 인한 
peryer’s patch 로의 통과(transcytosis)능력이 향상되는 것에 기인한다. 
마우스의 소장 peyer’s patch 로 들어가기 위한 CKS9-WSC-PLGA 
MPs 과 M 세포의 높은 결합친화성은 closed ileal loop assay 를 통해 
검증하였고 이는 공초점 레이저 현미경에 의해 결과로 제시되었다. 
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이러한 연구 결과로부터 CKS9-WSC-PLGA MPs 은 효과적인 경구 백신 
전달을 위한 유망한 방법임을 검증하였다. 
두 번째 연구는 경구백신의 항원 전달체로 생균제를 사용하기 위한 
목적으로 생균제를 경구로 투여하기 위한 전달체를 개발하는 것이다. 
생균제를 소장으로 전달하기 위한 가장 큰 장애물은 위산의 낮은 pH 로 
인한 생균제의 낮은 생존율을 극복하는 것이다. 이 연구는 생균제의 
생존율을 높이는 목적으로 백신을 발현하고 있는 생균제를 
알긴산/키토산/알긴산 마이크로캡슐에 캡슐화 시켜서 전달함으로써 
효과적인 백신 전달체를 개발하는 것이다. 이 연구는 M 세포 표적형 
펩타이드가 결합 된 BmpB 단백질을 발현하는 재조합 Lactobacillus 
plantarum25(LP25)을 모델 생균제로 사용하였다. 위의 환경을 모방한 
위액 (SGF, pH 2.0)과 소장의 환경을 모방한 소장액 (SIF, pH 7.2)에서 
2h 내에 캡슐화 된 LP25 의 생존율은 65%와 70%에 도달하였다. 또한 
캡슐화 된 LP25 는 SIF 에서 12h 내에 전 부 방출이 되는 것을 
확인하였다. 저장실험결과 실온과 4°C 에서 캡슐화 된 LP25 의 생존율은 
캡슐화 시키지 않은 LP25 에 비해 높은 것을 확인하였다. 흥미로운 것은 
캡슐화 된 LP25 의 경우 4°C 에서 5 주 후의 생존율은 58%에 달하는 
반면 캡슐화 되지 않은 LP25 의 경우 상온에서 5 주 후의 생존율은 
0%였다. 마우스 모델을 이용한 경구 면역실험에서 캡슐화 된 항원 생산 
LP25 를 경구투여 한 마우스에서 BmpB 특이적인 IgG 와 IgA 가 캡슐화 
되지 않은 생균제를 경구 투여한 마우스에 비해 많이 측정되었다. 
종합적으로 마이크로캡슐의 백신 생산 생균제의 캡슐화는 소화 
장관으로의 백신을 전달 할 수 있는 유망한 전달체임을 검증하였다. 
 
주요어: 경구 전달, M 세포 표적형 펩타이드, PLGA 마이크로 입자, 
BmpB, 키토산, 알긴산, 마이크로 캡슐화, Lactobacillus plantarum 25, 
생균제 
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